BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27624137)

  • 1. Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA.
    Pécuchet N; Rozenholc Y; Zonta E; Pietrasz D; Didelot A; Combe P; Gibault L; Bachet JB; Taly V; Fabre E; Blons H; Laurent-Puig P
    Clin Chem; 2016 Nov; 62(11):1492-1503. PubMed ID: 27624137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
    Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
    Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
    Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
    Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
    Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
    PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
    Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.
    Kukita Y; Uchida J; Oba S; Nishino K; Kumagai T; Taniguchi K; Okuyama T; Imamura F; Kato K
    PLoS One; 2013; 8(11):e81468. PubMed ID: 24278442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
    Paweletz CP; Sacher AG; Raymond CK; Alden RS; O'Connell A; Mach SL; Kuang Y; Gandhi L; Kirschmeier P; English JM; Lim LP; Jänne PA; Oxnard GR
    Clin Cancer Res; 2016 Feb; 22(4):915-22. PubMed ID: 26459174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
    J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter.
    Kukita Y; Ohkawa K; Takada R; Uehara H; Katayama K; Kato K
    PLoS One; 2018; 13(2):e0192611. PubMed ID: 29451897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel.
    Sato KA; Hachiya T; Iwaya T; Kume K; Matsuo T; Kawasaki K; Abiko Y; Akasaka R; Matsumoto T; Otsuka K; Nishizuka SS
    PLoS One; 2016; 11(1):e0146275. PubMed ID: 26727500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.
    Namba K; Tomida S; Matsubara T; Takahashi Y; Kurihara E; Ogoshi Y; Yoshioka T; Takeda T; Torigoe H; Sato H; Shien K; Yamamoto H; Soh J; Tsukuda K; Toyooka S
    BMC Cancer; 2019 Feb; 19(1):175. PubMed ID: 30808329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A newly developed capture-based sequencing panel for genomic assay of lung cancer.
    Im SW; Chae J; Jang SS; Choi J; Yun J; Cha S; Kwon NJ; Jeon YK; Hwang Y; Kim M; Kim TM; Kim DW; Kim JI; Kim YT
    Genes Genomics; 2020 Jul; 42(7):751-759. PubMed ID: 32449066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of tumor-derived DNA in plasma and bone marrow fluid in lung cancer patients.
    Goto T; Hirotsu Y; Oyama T; Amemiya K; Omata M
    Med Oncol; 2016 Mar; 33(3):29. PubMed ID: 26897174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pipeline for ctDNA Detection Following Primary Tumor Profiling Using a Cancer-Related Gene Sequencing Panel.
    Nishizuka SS; Sato KA; Hachiya T
    Methods Mol Biol; 2019; 1908():229-241. PubMed ID: 30649732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.
    Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S
    Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.